Two SNPs predict lithium response in bipolar I disorder

Two SNPs predict lithium response in bipolar I disorder

(HealthDay)—For patients with bipolar I disorder, two single nucleotide polymorphisms (SNPs) in glutamate decarboxylase-like protein 1 (GADL1) predict response to lithium, according to a study published online Dec. 25 in the New England Journal of Medicine.

Noting that many patients with bipolar disorders do not respond to lithium therapy, Chien-Hsiun Chen, Ph.D., from the Institute of Biomedical Sciences in Taipei, Taiwan, and colleagues assessed the response to in subgroups from a sample of 1,761 patients of Han Chinese descent with bipolar I disorder. A genome-wide association study was performed on a subgroup of 294 patients with bipolar I disorder who were receiving lithium. The SNPs with the strongest association with response were assessed in a replication sample of 100 patients and then in a follow-up sample of 24 patients. GADL1 was sequenced in 94 patients with a response to lithium and 94 without.

The researchers found that the strongest associations were seen for rs17026688 and rs17026651 in the genome-wide association study and in the replication sample of 100 patients. The sensitivity for predicting a response to lithium was 93 percent for these two SNPs, and they were able to differentiate between patients with a good and poor response in the follow-up cohort.

"Genetic variations in GADL1 are associated with the response to lithium maintenance treatment for bipolar I disorder in patients of Han Chinese descent," the authors write.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

The hunt for a successor to lithium for bipolar disorder

Mar 27, 2013

Toxicity problems and adverse side effects when taking lithium, the mainstay medication for treating bipolar disorder, are fostering a scientific hunt for insights into exactly how lithium works in the body—with an eye ...

New link identified for bipolar disorder

Jun 17, 2010

Lithium has been established for more than 50 years as one of the most effective treatments for manic depression, clinically termed bipolar disorder.

Giving lithium to those who need it

Sep 21, 2012

Lithium is a 'gold standard' drug for treating bipolar disorder, however not everyone responds in the same way. New research published in BioMed Central's open access journal Biology of Mood & Anxiety Disorders finds that t ...

Recommended for you

An alternative to medical marijuana for pain?

8 hours ago

Medical marijuana is proliferating across the country due to the ability of cannabis ingestion to treat important clinical problems such as chronic pain. However, negative side effects and the development of tolerance limit ...

Curtailing worry reduces key schizophrenia symptom

8 hours ago

Delusions of persecution in psychiatric patients can be reduced with just six sessions of cognitive behavioural therapy (CBT), a new clinical trial has found. Using CBT in this way could potentially help ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.